EntityRisk’s Post

The biotech market presents a challenging landscape characterized by its dynamic nature, technological complexities, and stringent regulatory requirements. The rapid pace of scientific innovation, coupled with the continuous evolution of biotechnological processes, demands constant adaptation from industry players. https://lnkd.in/e9CngMEU

Flagship Pioneering's latest move is shaking up the biotech world! Flagship, led by Noubar Afeyan, secured an impressive $3.6 billion in fresh funding, including $2.6 billion for Fund VIII, boosting their total capital pool to $10.9 billion! Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value. Key highlights from today's announcement (https://lnkd.in/eUXa7Qea): • $14 billion in assets under management • Plans to create and develop ~25 breakthrough companies • Focus areas: human health, sustainability, and AI • Global expansion with new hubs in London and Singapore • 100 person in-house drug development unit (Pioneering Medicines) with 10 therapeutics in pipeline and partnerships with Pfizer, Novo Nordisk, and the Cystic Fibrosis Foundation. Partnerships are at the heart of Flagship's strategy to accelerate scientific discoveries, tackle major health and sustainability challenges and boost value creation from portfolio companies. As a reminder, Newco LS18 Inc. (now Moderna) came out of Flagship (https://lnkd.in/eNT6bP-P)! This comes hot on the heels of their #3 ranking in Fast Company's Most Innovative Companies list (https://lnkd.in/e-w7gc4a). Flagship's unique Innovation Supply Chain Partnership model is reshaping R&D in biotech. I look forward to seeing how they continue to impact biotech and patient lives. How do you think this new fund will impact our industry? #Biotech #Innovation #VentureCapital #Health #Sustainability #Partnerships

🔬💡 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Adapting for Success 💊🌱 🌱 In the realm of drug development, 𝐃𝐚𝐫𝐰𝐢𝐧'𝐬 𝐭𝐢𝐦𝐞𝐥𝐞𝐬𝐬 𝐰𝐢𝐬𝐝𝐨𝐦 rings true: "It is not the strongest of the species that survives, nor the most intelligent. It is the one most responsive to change." 🔄 This adage underscores the necessity for 𝐚𝐝𝐚𝐩𝐭𝐚𝐛𝐢𝐥𝐢𝐭𝐲 in an ever-evolving landscape. The journey of drug development mirrors the process of natural selection. Just as species must adapt to thrive in their environment, drug development must continuously respond to new challenges and opportunities. 👥 One of the driving forces behind this adaptation is collaboration. Like ecosystems thriving on symbiotic relationships, drug development flourishes when 𝐚𝐜𝐚𝐝𝐞𝐦𝐢𝐚, 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐜𝐚𝐩𝐢𝐭𝐚𝐥𝐢𝐬𝐭𝐬, and 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 work hand in hand. This collaborative spirit fuels innovation within biotech firms, propelling breakthroughs in targeted therapies and accelerating drug development cycles. ⏱️ However, while the financial model has adapted well, portfolio strategy and operationalization have been slower to catch up. There's a pressing need for innovative operating models that match the pace of therapeutic innovation, optimizing capital and human resource allocation for better returns on investment. 🎯 But is the biotech ecosystem ready for such a shift? The answer lies in embracing key features of this new model: optimized resource allocation and recognition of portfolio synergies, leading to significant time and cost savings. 𝐖𝐡𝐲 𝐧𝐨𝐰❓❓ 🌟 We're amidst a golden age of biotech innovation, where adopting a tailored operating model is not just advantageous but essential for sustaining and enhancing success. This model aligns with the core structures of biotech organizations, facilitating agility and efficiency crucial for navigating this dynamic industry. 🌿 In conclusion, just as Darwin's theory remains relevant in nature, its principles are evident in the dynamic landscape of drug development, where adaptability, collaboration, and innovation are key to survival and success. Let's continue to evolve and adapt, shaping a brighter future for healthcare together. 💪💊 . . . #drugdevelopment #innovation #Biotech #Collaboration #research #ubuntu #ubunturesearch

FAIR data policies can benefit biotech startups! I am pleased to see that our Signal Research Suit platform apply FAIR data policies and can assist biotech startups in their journey!  To the life science startup, data is arguably its most important asset. Establishing FAIR data practices from the start can provide direct benefits throughout the lifetime of the company. In contrast to big pharma, BIG pharma companies that must undertake costly retrospective efforts to ‘FAIRify’ legacy data, startups have a unique and short-lived opportunity to position themselves to reduce program delays, innovate faster, enhance security, and beyond. The main goal of Revvity Signals Research Suite is to help both Startup and large pharmaceutical companies establish FAIR data practices. Data within the Signals Research Suite is findable, accessible, interoperable, and reproducible (FAIR), aiding in data integrity and regulatory compliance. These makes it a suitable platform (especially for biotech startups) to accelerate drug development. #FAIR #data #dataanalysis #automation #Startup #drugdevelopment #biotech #RevvitySignals #SignalsResearchSuite https://lnkd.in/gcxmh_H9

𝐒𝐜𝐢𝐨𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐰𝐢𝐭𝐡 𝐎𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 $𝟑𝟏𝟎 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐅𝐮𝐧𝐝 𝐭𝐨 𝐂𝐫𝐞𝐚𝐭𝐞 𝐄𝐱𝐜𝐞𝐩𝐭𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 Scion Life Sciences Scion Life Sciences, based in NYC and led by seasoned partners Samuel W. Hall Sam Hall, PhD, Aaron M. Kantoff Aaron Kantoff, and Tadd S. Wessel Tadd Wessel of Petrichor Petrichor, announces the final close of its inaugural fund. With a mission to develop transformative medicines, Scion is committed to founding and nurturing biotech startups. Scion's approach focuses on mature therapeutic modalities, deep scientific understanding, and addressing clinical needs with independent resources. The firm's strategic pillars mitigate risk and increase the likelihood of delivering life-changing treatments. "We're dedicated to solving critical clinical challenges and providing long-term support to build sustainable biotech companies," says Sam Hall Sam Hall, PhD. Scion has already initiated investments in four promising startups and established Scion Innovations to enhance R&D capabilities. This proactive, data-driven approach aims to create impactful medicines and sustainable companies. "We prioritize creating significant new medicines over exits," says Aaron Kantoff Aaron Kantoff. "Our approach, combined with a long-term fund structure, positions us to build biotech companies capable of transforming patient lives." "We're grateful for the trust of our partners who share our vision for impactful medicine creation," adds Tadd Wessel Tadd Wessel . #Biotech #VentureCapital #Investment #Medicine #ClinicalResearch #Biotechnology #Pharmaceuticals #TransformativeMedicine #DrugDevelopment #HealthTech #Entrepreneurship

As professionals deeply passionate about advancing healthcare and creating a positive impact, this article resonated with me. It discusses the reasons behind the "biotech winter" - a period marked by funding challenges, regulatory hurdles, and stagnation in the pace of innovation. However, it also presents a compelling case for optimism, hinting at signs that the winter might finally be thawing. Key trends, such as increased investment in biotech startups, groundbreaking advancements in gene editing technologies, and the emergence of new partnerships between biotech firms and other industries are painting a promising picture for the future of biotechnology and its potential to revolutionize medicine and healthcare as we know it. As we navigate through the ever-changing landscape of the biotech industry, I believe it's crucial to stay informed and engaged. This article serves as a reminder that despite the challenges, we are witnessing groundbreaking strides in science and technology. Let's continue to foster collaboration, support innovation, and push the boundaries of what's possible. https://lnkd.in/gmfbxreb #BiotechIndustry #Innovation #Healthcare #BiotechAdvancements #ScienceandTechnology #Medicine #Collaboration #Impact

In this week’s Pro Briefing, we look at the highly adventurous end of the healthcare spectrum: the world of cutting-edge biology. 🧬 2023 has seen a flurry of dealmaking, with an uptick in M&As and some big raises and approvals of new drugs for vexing diseases. 🌎 13 countries have attracted 74% of biotech funding from 2020 to 2021 💸 $85bn is the global biopharma spend on acquisitions in first five months of 2023 👀 40k patents have been granted for biotechs in Europe in last five years ⭐ The industry’s rising stars? Engimmune Therapeutics, MicrofluidX, Nostos Genomics and Finnadvance. Inside you’ll also find 151 early-stage startups to watch — selected by our Intelligence team after extensive scouting of the ecosystem. Discover more: https://hubs.ly/Q022cXVz0 — —  What are Briefings? Exclusive to our Pro subscribers, we provide investment-grade research on over 95 sectors and geographies — so you can stay up to speed, fast. ➡️ Learn more: https://hubs.ly/Q022d09y0 #biotech #startups #investors #SiftedPro #biotechnologyindustry #biotechnews

📢 Join the Startup Spotlight at #BIOEurope 2023!   Apply now to pitch & win: 🚀 Take your business to the next level with the great chance to connect with prominent investors and key figures in the #biotech industry at BIO-Europe organized by EBD Group. Pitch to a selected jury, participate in a live feedback session and win awards > 10.000 EUR! All selected pitchers get full access to BIO-Europe partnering. The first place winner will receive 8.000 EUR sponsored by Bayer | Pharmaceuticals, access to Bayer’s mentoring programs and will be shortlisted for Bayer Co.Lab’s state-of-the-art Co.Lab incubator. The second place winner will receive 2.000 EUR. Don’t miss out on this opportunity to get your company noticed, funded, and claim your place as the next generation biotech breakthrough. ➡ Apply until Sep 8 here: https://lnkd.in/gf7zueFY ℹ Don't want to pitch but register for BIO-Europe 2023 as a start-up or young company? Here you go: https://lnkd.in/dFZ7BBx (scroll down completely, there you will find a good overview, incl. the Young Company Rate and link to registration: https://lnkd.in/eg5Ndqdk)

If you are a scientist or a medical doctor who wants to start a company, here is a powerful resource to help you translate your scientific innovation into VC-language "Template for Pharma and Biotech Startup Pitch Deck (VC-reviewed) with Quick Guide”. (Reviewed by 21 VCs actively investing in biotech and pharma startups). #template #biotech #vc Go to https://lnkd.in/e-Wq_sAE